2
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Calorimetric Studies of Binary and Ternary Molecular Interactions between Transthyretin, Aβ Peptides, and Small-Molecule Chaperones toward an Alternative Strategy for Alzheimer’s Disease Drug Discovery

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Transthyretin (TTR) modulates the deposition, processing, and toxicity of Abeta (Aβ) peptides. We have shown that this effect is enhanced in mice by treatment with small molecules such as iododiflunisal (IDIF, 4), a good TTR stabilizer. Here, we describe the thermodynamics of the formation of binary and ternary complexes among TTR, Aβ(1–42) peptide, and TTR stabilizers using isothermal titration calorimetry (ITC). A TTR/Aβ(1–42) (1:1) complex with a dissociation constant of K d = 0.94 μM is formed; with IDIF ( 4), this constant improves up to K d = 0.32 μM, indicating the presence of a ternary complex TTR/IDIF/Aβ(1–42). However, with the drugs diflunisal ( 1) or Tafamidis ( 2), an analogous chaperoning effect could not be observed. Similar phenomena could be recorded with the shorter peptide Aβ(12–28) ( 7). We propose the design of a simple assay system for the search of other chaperones that behave like IDIF and may become potential candidate drugs for Alzheimer’s disease (AD).

          Related collections

          Most cited references70

          • Record: found
          • Abstract: found
          • Article: found
          Is Open Access

          The amyloid hypothesis of Alzheimer's disease at 25 years

          Abstract Despite continuing debate about the amyloid β‐protein (or Aβ hypothesis, new lines of evidence from laboratories and clinics worldwide support the concept that an imbalance between production and clearance of Aβ42 and related Aβ peptides is a very early, often initiating factor in Alzheimer's disease (AD). Confirmation that presenilin is the catalytic site of γ‐secretase has provided a linchpin: all dominant mutations causing early‐onset AD occur either in the substrate (amyloid precursor protein, APP) or the protease (presenilin) of the reaction that generates Aβ. Duplication of the wild‐type APP gene in Down's syndrome leads to Aβ deposits in the teens, followed by microgliosis, astrocytosis, and neurofibrillary tangles typical of AD. Apolipoprotein E4, which predisposes to AD in > 40% of cases, has been found to impair Aβ clearance from the brain. Soluble oligomers of Aβ42 isolated from AD patients' brains can decrease synapse number, inhibit long‐term potentiation, and enhance long‐term synaptic depression in rodent hippocampus, and injecting them into healthy rats impairs memory. The human oligomers also induce hyperphosphorylation of tau at AD‐relevant epitopes and cause neuritic dystrophy in cultured neurons. Crossing human APP with human tau transgenic mice enhances tau‐positive neurotoxicity. In humans, new studies show that low cerebrospinal fluid (CSF) Aβ42 and amyloid‐PET positivity precede other AD manifestations by many years. Most importantly, recent trials of three different Aβ antibodies (solanezumab, crenezumab, and aducanumab) have suggested a slowing of cognitive decline in post hoc analyses of mild AD subjects. Although many factors contribute to AD pathogenesis, Aβ dyshomeostasis has emerged as the most extensively validated and compelling therapeutic target.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            2019 Alzheimer's disease facts and figures

            (2019)
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Thioflavine T interaction with synthetic Alzheimer's disease beta-amyloid peptides: detection of amyloid aggregation in solution.

              H. Levine (1993)
              Thioflavine T (ThT) associates rapidly with aggregated fibrils of the synthetic beta/A4-derived peptides beta(1-28) and beta(1-40), giving rise to a new excitation (ex) (absorption) maximum at 450 nm and enhanced emission (em) at 482 nm, as opposed to the 385 nm (ex) and 445 nm (em) of the free dye. This change is dependent on the aggregated state as monomeric or dimeric peptides do not react, and guanidine dissociation of aggregates destroys the signal. There was no effect of high salt concentrations. Binding to the beta(1-40) is of lower affinity, Kd 2 microM, while it saturates with a Kd of 0.54 microM for beta(1-28). Insulin fibrils converted to a beta-sheet conformation fluoresce intensely with ThT. A variety of polyhydroxy, polyanionic, or polycationic materials fail to interact or impede interaction with the amyloid peptides. This fluorometric technique should allow the kinetic elucidation of the amyloid fibril assembly process as well as the testing of agents that might modulate their assembly or disassembly.
                Bookmark

                Author and article information

                Journal
                J Med Chem
                J. Med. Chem
                jm
                jmcmar
                Journal of Medicinal Chemistry
                American Chemical Society
                0022-2623
                1520-4804
                03 March 2020
                26 March 2020
                03 March 2021
                : 63
                : 6
                : 3205-3214
                Affiliations
                []Institut de Química Avançada de Catalunya (I.Q.A.C.-C.S.I.C.) , 08034 Barcelona, Spain
                []CIC bioGUNE, Basque Research and Technology Alliance (BRTA) , Bizkaia Technology Park, Building 800, 48160 Derio, Spain
                [§ ]CIC biomaGUNE, Basque Research and Technology Alliance (BRTA) , 20014 San Sebastian, Spain
                []Ikerbasque, Basque Foundation for Science , Maria Diaz de Haro 13, 48009 Bilbao, Spain
                []Department of Organic Chemistry II, Faculty of Science & Technology, University of the Basque Country , 48940 Leioa, Bizkaia, Spain
                [# ]Research Programme on Biomedical Informatics, Universitat Pompeu Fabra (UPF-IMIM) , 08003 Barcelona, Spain
                []IBMC—Instituto de Biologia Molecular e Celular , 4200-135 Porto, Portugal
                []i3S—Instituto de Investigação e Inovação em Saúde, Universidade do Porto , 4200-135 Porto, Portugal
                []Unitat de Polimorfisme i Calorimetria, Centres Científics i Tecnològics, Universitat de Barcelona , Baldiri Reixac 10, 08028 Barcelona, Spain
                Author notes
                Article
                10.1021/acs.jmedchem.9b01970
                7115756
                32124607
                c41dccc7-06a0-45bd-8aa9-e796016f1b13
                Copyright © 2020 American Chemical Society

                This is an open access article published under a Creative Commons Non-Commercial No Derivative Works (CC-BY-NC-ND) Attribution License, which permits copying and redistribution of the article, and creation of adaptations, all for non-commercial purposes.

                History
                : 27 November 2019
                Categories
                Article
                Custom metadata
                jm9b01970
                jm9b01970

                Pharmaceutical chemistry
                Pharmaceutical chemistry

                Comments

                Comment on this article